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properties in a mouse model of chronic
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Poor oral availability and susceptibility to reduction and protease degradation is a major
hurdle in peptide drug development. However, drugable receptors in the gut present an
attractive niche for peptide therapeutics. Here we demonstrate, in a mouse model of chronic
abdominal pain, that oxytocin receptors are significantly upregulated in nociceptors inner-
vating the colon. Correspondingly, we develop chemical strategies to engineer non-reducible
and therefore more stable oxytocin analogues. Chemoselective selenide macrocyclization
yields stabilized analogues equipotent to native oxytocin. Ultra-high-field nuclear magnetic
resonance structural analysis of native oxytocin and the seleno-oxytocin derivatives reveals
that oxytocin has a pre-organized structure in solution, in marked contrast to earlier X-ray
crystallography studies. Finally, we show that these seleno-oxytocin analogues potently
inhibit colonic nociceptors both in vitro and in vivo in mice with chronic visceral hypersen-
sitivity. Our findings have potentially important implications for clinical use of oxytocin
analogues and disulphide-rich peptides in general.
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S
ince its discovery over a century ago, few bioactive peptides
have proven to be more important and widely studied than
the peptide hormone oxytocin (OT)1. OT was the first
peptide hormone to be sequenced and synthesized, an
achievement recognized with the award of the 1955 Nobel Prize
in Chemistry to Vincent du Vigneaud2. OT has since become
widely used in obstetrics to induce labour, prevent post-partum
haemorrhage and stimulate lactation in nursing mothers3. In the
central nervous system, OT functions as a neurotransmitter
involved in complex social interactions, including maternal
behaviour, partnership and social bonding4. Recent studies have
shown that OT function (and that of the closely related hormone
vasopressin) is impaired in brain disorders associated with social
dysfunction such as autism, social anxiety, stress and
schizophrenia, triggering an explosion of interest in the use of
OT for treatment of mental conditions5,6. OT receptors have also
attracted attention for their role in memory7, breast cancer
tumour growth8 and visceral pain9,10. Nasal administration of OT
reduces abdominal pain and discomfort in patients with chronic
idiopathic constipation9, whereas continuous intravenous OT
significantly increases thresholds for visceral perception in
patients with Irritable Bowel Syndrome (IBS)10. The
mechanisms underlying these effects remain unclear and are
important to determine as chronic abdominal pain represents a
major clinical problem, with IBS alone affecting B11% of the
Western population11.
With many clinical trials currently underway to investigate OT
effects in a wide range of diseases12 it is imperative to advance
strategies that improve the metabolic stability and drug-like
properties of this unique signaling hormone and
neurotransmitter. In this study, we disclose several insights into
OT. We describe the well-defined structure of OT in aqueous
solution and present an efficient strategy for production of more
stable analogues based on seleno-chemistry. Finally, we
demonstrate that OT receptor expression and function is
significantly upregulated in colonic neurons of mice with
chronic visceral hypersensitivity (CVH) and show that stable
OT analogues are potently analgesic in this animal model of
chronic abdominal pain. Taken together, our results indicate that
stable OT analogues have significant potential for the treatment
of chronic abdominal pain associated with conditions such as IBS.
Results
OT analogues with an engineered selenoether bridge. OT is a
cyclic peptide comprising nine amino-acid residues with a single
disulphide bridge between the first and sixth residues. The
disulphide bond is critical for binding to the OT receptor;
however, it renders the peptide susceptible to endogenous
reductive degradation3. Although replacement of the labile
bridge with a more redox-stable linkage is an attractive
approach to improve the metabolic integrity of OT, it is non-
trivial for OT, as its biological activity is sensitive to minute
structural modifications within the cyclic framework. Even
minor distortions such as increasing the 20-membered ring by
one methylene group13, substitution of Cys1 by penicillamine14
or replacement of the disulphide bond by an amide15,
lanthionine16 or dicarba17 bond leads to a significant decrease
in agonist activity. In contrast, OT bioactivity is retained when
the OT S-S bond is replaced by chalcogen linkages such as
cystathionine (CH2-S, Ctt), diselenide (Se-Se), selenylsulphide
(Se-S) and ditelluride (Te-Te) bonds, where the 20-membered
ring framework is conserved16. Of particular interest for drug
development is the close isomorphism between disulphides and
non-reducible Ctt bonds18,19. Carbetocin, a Ctt analogue of
desamino-OT, is an example of a long-acting disulphide bond
mimetic that is approved as a drug20.
Conventional intramolecular S-alkylation of cysteine used to
build Ctt bridges in cyclic peptides is often problematic (Fig. 1a)
and, with few exceptions18,19,21,22, has not found broad
application in the field of peptide chemistry. Here we describe a
macrocyclization strategy that exploits the advantageous
physicochemical properties of selenocysteine (Sec, U) instead of
cysteine to accomplish effective crosslinking that can be applied
not only to native OT but also to a wide range of other peptide
sequences. In recent years, Sec has been incorporated into several
bioactive peptides with innovative properties23,24. For example,
substitution of S-S bonds by isosteric Se-Se bonds can improve
peptide folding and stability25–27. We envisaged that replacement
of a disulphide bond (S-S, bond length 2.03 Å)28 by a non-
reducible selenocystathionine (SeCtt) bond (Se-C, bond length
1.95–1.99Å)28 might enhance the metabolic stability of cyclic
peptides with minimal structural perturbation. Furthermore, the
low pKa of the selenol in Sec29 should allow selenide ring closure
1 to proceed efficiently under acidic to neutral conditions, largely
preventing deterioration of labile electrophilic moieties at higher
pH (Fig. 1b).
Synthesis of linear peptide precursors. In order to investigate
the scope of SeCtt cyclization in comparison with Ctt cyclization,
a series of linear OT sequences featuring Sec, Cys and haloge-
nated residues at the corresponding sites of the native Cys1–Cys6
disulphide bond were synthesized by solid-phase peptide
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Figure 1 | Synthesis of Ctt and SeCtt cyclic peptides. (a) Synthesis of Ctt cyclic peptides by intramolecular SN2-substitution of a g-halo-homoalanine by
cysteine21,22 and possible degradation products of the linear precursor. Under the basic conditions required for monosulphide cyclization, the g-halo-
homoalanine residue can undergo intramolecular lactonization or be hydrolyzed to homoserine. (b) Intramolecular ring closure of a SeCtt cyclic peptide.
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synthesis (SPPS) (Fig. 2). The linear precursors 2, 3 and 4
were assembled on a Rink amide resin using standard Fmoc
chemistry (Fig. 2a)30. The crucial chlorination step, where
the tert-butyl dimethylsilyl (TBDMS)-protected homoserine
(Hse) is converted to g-chloro-homoalanine (gCl-hAla)18,
was performed in a mixture of PPh3 and CCl3CN in
dichloromethane (DCM) overnight. Surprisingly, chlorination
treatment also removed the p-methylbenzyl (MeBzl) protecting
group of the Sec residue in precursor 2, thus yielding diselenide 5
upon trifluoroacetic acid (TFA) cleavage. Likewise, the
chlorinated intermediate 6 was prepared from Cys-peptide 3,
while on-resin bromination of precursor 4 with PPh3Br2
transformed the TBDMS-protected Hse to a g-bromo-
homoalanine to give 7 in moderate yield. A similar
bromination step was unsuccessful for peptides 2 and 3. Using
Boc chemistry, the resin-bound 8 containing bromide and Sec
moieties was prepared by coupling of Fmoc-gBr-hAla21 9 during
peptide assembly as illustrated in Fig. 2b. Removal of the
N-terminal Fmoc group using piperidine and subsequent
cleavage from the resin by HF acidolysis afforded precursor 10
in modest yield. In a more efficient synthesis, the chlorinated
Se-precursor 11 was prepared by Boc chemistry utilizing the
b-chloro-alanine and selenohomocysteine (SeHcy, hU)-building
blocks during peptide assembly (Fig. 2c).
Selenoether and thioether cyclizations. The key feature of the
selenoether cyclization step is reduction of the diselenide peptide
precursor by dithiothreitol (DTT) with concomitant intramole-
cular Se-alkylation of the generated selenolate (Fig. 3a)31.
Cyclization of precursor peptides 5–7 and 10–11 was carried
out with 100mM precursor in sodium phosphate buffer at
different pH using 40-fold excess DTT (Table 1). The ring-closing
reaction was performed at room temperature (RT) and
monitored via analytical reversed phase high-performance
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Figure 2 | Synthesis of the linear halogenated Sec- and Cys-containing OT precursors. (a) By Fmoc chemistry via chlorination or bromination on
resin. (b) By Boc chemistry with coupling of a Fmoc-gBr-hAla residue. (c) By Boc chemistry via coupling of a b-chloro-alanine and SeHcy residues.
Asterisks indicate that standard side-chain-protecting groups were used for the respective residues during SPPS. Reagents and conditions:
(i) PPh3/CCl3CN, DMF, overnight; (ii) TFA:TIS:H2O, 2 h; (iii) PPh3Br2, DCM, overnight; (iv) 20% piperidine in DMF, 1 min; (v) HF:p-cresol (9:1), 0 C, 1 h.
Table 1 | Linear precursors to the cyclic OT analogues.
Linear precursor Cyclic oxytocin
A B Name
10, 11 CH2 Se SeCtt 12
7 CH2 S Ctt 13
5 Se CH2 SeCtt 14
6 S CH2 Ctt 15
Se SeLan 16
S S OT
OT, oxytocin.
See Fig. 3d for general cyclic OT structure.
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liquid chromatography (RP-HPLC). Reduction of the g-bromo-
diselenide precursor 10 gave SeCtt 12 in excellent conversion
(80–98% over a wide pH range) (Fig. 3a,b). At pH 5–11, 12 was
formed within 2 h, whereas several hours were required for
reactions at pH 3–4 (Supplementary Fig. 1). In contrast, the
reaction time for thiolation using the analogous g-bromo-thiol-
precursor 7 took 2–4 times longer and macrocyclization was
diminished (Fig. 3b). Under optimal conditions, gBr-hAla
Cys-intermediate 7 was 42% converted to Ctt 13 (pH 11), while
gBr-hAla Sec-precursor 10 was quantitatively converted to
SeCtt 12 (98%) at pH 5.5 (Fig. 3c). The formation of the
selenoether or thioether ring was slower (8–72 h depending on
pH) using gCl-hAla in comparison with the bromo-counterpart
(Supplementary Fig. 1). The gCl-hAla Sec peptide 5 cyclized to
SeCtt 14 in 68–86% transformation, while its cysteine-containing
counterpart gCl-hAla Cys-peptide 6 cyclized to Ctt 15 poorly
(o 32%) even at basic pH (Fig. 3b). SeCtt 12 was also produced
from 11; however, in this case, the intramolecular SN2
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Figure 3 | Selenoether and thioether cyclizations. (a) Schematic representation of the cyclization of g-bromo seleno-precursor 10 to selenoether 12.
(b) Conversion (%) of the precursors 10, 5, 11, 6 and 7 into the respective cyclic products (Table 1) under DTT-reductive conditions at variable pH
determined using HPLC. (c) HPLC analysis of the cyclization reaction under optimal conditions (Ctt 13 and 15, pH 11; SeCtt 12, pH 5.5 (from precursor 10)
and pH 8.3 (from precursor 11); SeCtt 14, pH 5.5). Asterisks mark the retention time for the cyclic products, while arrows indicate retention time
of the respective linear precursors. The numbers in italics are the extent of conversion (%) of the linear precursor into the respective macrocycle.
Major side products found during thioether cyclization (Fig. 1a) are indicated as peak ‘a’ (fragmentation by intramolecular lactonization) and
‘b’ (hydrolysis to homoserine). (d) General structure of the cyclic OT analogues. A, B: see Table 1.
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substitution was only effective under basic conditions due to lower
reactivity of the SeHcy synthon (Fig. 3b). Nevertheless, selenoether
formation proceeded smoothly over 72 h at pH 8.3 with no
detectable deterioration of the b-chloro-alanine moiety (Fig. 3c).
On the basis of the results obtained for synthesis of the linear
precursors and their cyclization efficiency, we chose the chloro-
peptides 11 and 5 for preparative synthesis of SeCtt OT analogues
12 and 14, respectively. DTT-induced cyclization was performed
directly on crude peptides after cleavage from resin. Selenoether
crosslinking of 5 at pH 5.5 gave pure SeCtt 14 in 42% overall
yield, whereas precursor 11 at pH 8.3 gave pure SeCtt 12 in 27%
overall yield. All compounds were purified to 495% purity via
RP-HPLC and characterized using mass spectrometry and
nuclear magnetic resonance (NMR).
Thermal and plasma stability of the selenoether OT analogues.
To evaluate their chemical stability, OT peptides were submitted
to thermal stress at 55 C, pH 7.2 (Fig. 4a). Native OT degraded
significantly over 3 days at 55 C, with a half-life of 2.2 days, as a
result of disulphide bond disruption32. These side reactions were
not observed with the SeCtt analogues and linkages remained
mostly intact under these conditions (calculated half-lives for
SeCtts 12 and 14 were 51.3 and 11.3 days, respectively). Metabolic
stability studies yielded a half-life of 16 h for OT in human serum
at physiological pH and 37 C (Fig. 4b), whereas the half-lives for
SeCtt 12 and 14 decay was 60 and 50 h, respectively. The three- to
four fold increase in plasma stability is similar to that reported for
Ctt 13 (ref. 16).
Functional activity of the selenoether OT analogues. The
pharmacological activity of native OT, Ctt and SeCtt OT was
assessed in a functional Ca2þ mobilization assay using the
human neuroblastoma cell line SH-SY5Y that endogenously
expresses OT receptors33. All SeCtt and Ctt OT analogues showed
similar agonist activity to the parent hormone (Supplementary
Table 1). In comparison, the selenoether derivative SeLan 16, an
OT surrogate with a selenolanthionine linker (Table 1) whose
synthesis we recently reported31, showed loss of bioactivity.
NMR structure analysis of OT and selenoether OT 14 and 16.
Currently, there are two crystal structures available for OT
unbound desamino-OT34 and a complex of OT with its carrier
protein neurophysin35. These OT structures are very different; the
bound form reveals a helical fold for the OT ring, while the free
form is more consistent with b-sheet structure (displaying Type II
and III b-turns). The first NMR studies of OT conducted in the
1970s led the authors to propose a flexible structure for OT based
solely on temperature coefficients and chemical shift
information36. Later, NMR studies of OT were focused on its
conformation when bound to neurophysin37. This latter study
reported a lack of inter-residue dipolar connectivities in the
absence of neurophysin, and subsequent studies have therefore
assumed that OT is flexible and unstructured in solution38. This
has led to the suggestion that binding to the OT receptor may
occur through a receptor-induced fit34. Here we re-examined the
solution structure of free OT using multidimensional
heteronuclear NMR spectroscopy at ultra-high field (900MHz).
The use of ultra-high magnetic field in combination with a
cryogenically cooled probe enabled us to overcome the lack of
cross peaks observed in nuclear O¨verhauser enhancement
spectroscopy (NOESY) spectra acquired on less sensitive, lower-
field instruments38. The frequencies of all 1H atoms (except those
absent due to fast exchange with solvent) were assigned using
homonuclear total correlation spectroscopy and NOESY spectra,
while all protonated heteroatoms were assigned using
heteronuclear HSQC spectra. The selenoether bond was
assigned using a 1H-77Se HMQC spectrum, where correlations
from the Se atom could be observed to protons of neighbouring
carbon atoms (Fig. 5a)39. Structures were calculated using the
torsion angle dynamics program CYANA 3.0 (ref. 40) using
torsion angle restraints derived from 1H/13C/15N chemical shifts
and distance restraints derived from 1H–1H NOEs. The results
are summarized in Fig. 5 and Supplementary Tables 2,3.
All structures had excellent stereochemistry, although residue
G9 is an outlier in the Ramachandran plot and poor side-chain
rotamers were occasionally observed for residues Y2 and L8. In all
structures, a hydrogen bond was identified between the backbone
amide proton of residue X6 and the backbone carbonyl oxygen of
Y2. An additional hydrogen bond was found between the
backbone amide proton of N5 and the carbonyl oxygen of Y2.
The backbone chemical shifts of residues 7–9 are consistent with
random coil values and were predicted to be dynamic by
Talosþ 41, in agreement with previous studies (region coloured in
red in Fig. 5b)38. The unfavourable NMR properties of sulphur
make disulphide bonds largely ‘invisible’ in NMR studies42; in
contrast, the SeCtt analogue provided structural constraints
through 77Se couplings to neighbouring methylenes while the
additional methylene within the hydrophobic core 14 generated
extra distance restraints.
Analgesic action of OT and selenoether analogues. In order to
translate these findings to an intact physiological setting and to
determine the mechanism of action of OT-induced analgesia in
patients with abdominal pain associated with chronic idiopathic
constipation9 or IBS10, we determined the level of OT receptor
expression in colonic afferent dorsal root ganglion (DRG)
neurons and tested the analgesic properties of native OT and
the OT analogues SeCtt 12 and SeCtt 14 on sensory nociceptive
afferents innervating the colon.
First, we examined expression of the OT receptor in colonic
afferent neuronal cell bodies. As only 5% of DRG neurons
innervate the colon, we used retrograde nerve tracing from the
colon wall to specifically identify afferent neurons in the DRG
supplying the colon43–45. Laser capture microdissection was then
used to isolate the labelled neurons from dissociated DRG
cultures, giving a pure colonic afferent neuron population. These
studies were performed in healthy mice and in a mouse model of
post-inflammatory CVH, which was induced with intra-colonic
trinitrobenzene-sulphonic acid (TNBS), as described
previously46,47. The TNBS-treated mice were allowed to recover
for 28 days, at which stage inflammation had resolved and
chronic colonic afferent mechanical hypersensitivity46,47 and
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Figure 4 | Selenoether analogues are more stable than native OT.
(a) Thermal stability of OT and SeCtt analogues 12 and 14 at pH 7 and
55 C. (b) Stability of OTand analogues 12 and 14 in human plasma. Peptide
levels were quantified using LC-MS (n¼ 3). All data are Mean±SEM.
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hyperalgesia48,49 were evident. We chose this model as it is being
increasingly appreciated that gastrointestinal inflammation can
precede IBS symptom development and that low-grade
inflammation, mast cell infiltration, and immune dysfunction
are evident in different subgroups of IBS patients43,50–52.
Furthermore, chronic visceral mechanical hypersensitivity of
colonic afferents is implicated in the development and
maintenance of visceral pain in IBS53–55. As such these mice
are termed CVH mice46,47.
Quantitative RT–PCR analysis and gel electrophoresis showed
that the OT receptor expression was below the level of detection
in healthy thoracolumbar (TL; T10–L1) colonic DRG neurons
(Fig. 6a,b). In contrast, OT receptor expression was significantly
upregulated in colonic TL DRG neurons from CVH mice
(Fig. 6a,b). We then determined the effects of native OT and
the OT analogues on colonic afferent function56. We specifically
targeted high-threshold nociceptive afferents in the splanchnic
(thoracolumbar) pathway as we have shown that they normally
respond to noxious levels of colonic distention/contraction45,46.
These afferents are known to become hypersensitive46,47 and
hyper-excitable57,58 in models of chronic visceral pain, which
translates to increased signaling of noxious colorectal distention
(CRD) within the thoracolumbar spinal cord59 and enhanced
behavioural responses to CRD48,49. We have also shown that
specific functional deficits in these afferents translate to reduced
sensory responses to noxious CRD in whole-animal studies45.
Correspondingly, in the current study we show that with in vitro
colonic afferent recordings43–47,56 native OT, SeCtt 12 and SeCtt
14 had no effect on colonic nociceptor mechanosensitivity in
healthy mice (Fig. 6c–e and Supplementary Fig. 2). However, in
recordings from nociceptors from CVH mice we found that
native OT, SeCtt 12 and SeCtt 14 all significantly and dose-
dependently inhibited the mechanical hypersensitivity observed
in CVH colonic nociceptors (Fig. 6f–h and Supplementary Fig. 2).
Overall, both SeCtt 12 and SeCtt 14 caused greater inhibition of
colonic nociceptors than that induced by native OT (Fig. 6i–k and
Supplementary Figs 2,3). Notably, we also found that the
inhibitory effect of SeCtt 14 can be blocked by prior luminal
administration of the OT receptor antagonist, atosiban
(Supplementary Fig. 4).
Since native OT and OT analogues SeCtt 12 and SeCtt 14
inhibit colonic nociceptors in vitro, we hypothesized that
this inhibition should correspondingly reduce signaling of
noxious CRD within the spinal cord in vivo. We administered
the OT analogue SeCtt 14 intra-colonically as this route
of administration complements the conditions used in our
in vitro studies. It also allowed us to ensure peripheral exposure
to OT analogue SeCtt 14 for equal time durations, with
minimal systemic actions. Furthermore, we recently used this
route of administration to demonstrate the preclinical efficacy
of a pharmacological treatment that reduces chronic abdominal
pain and is poorly systemically absorbed and thus its effects
are localized to the gastrointestinal tract47. We identified neurons
in the dorsal horn (DH) of the thoracolumbar spinal
cord activated by noxious CRD (Fig. 7a and Supplementary
Fig. 5). In healthy mice, intra-colonic administration of SeCtt 14
had no effect on the number of DH neurons activated in the
thoracolumbar spinal cord following noxious CRD (Fig. 7b–d and
Supplementary Fig. 5), consistent with the lack of anti-nociceptive
effect of native OT and OT analogues we showed in vitro (Fig. 6).
In contrast, intra-colonic administration of SeCtt 14 in CVH
mice resulted in a significant reduction in the number of DH
neurons activated in the thoracolumbar spinal cord following
noxious CRD (Fig. 7e–g and Supplementary Fig. 5). Overall, our
data indicate that OT analogues reduce nociceptive signaling
and reverse chronic visceral mechanical hypersensitivity both
in vitro and in vivo but only during states of CVH and not in
healthy mice.
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Figure 5 | Structural characterization. Structural characterization of OT and selenium analogues by NMR at 298K and comparison to crystal structures.
(a) Portions of 1H-77Se HMQC and 1H–13C HSQC spectra of the bioactive selenoether 14. The 1H–13C HSQC spectrum shows correlations between
the b carbons and their attached protons (at 1H frequency of 900MHz). The 1H-77Se HMQC spectrum shows correlations between the Se atom and
protons two bonds away (at 1H frequency of 500MHz). A 900-MHz 1D 1H NMR spectrum is shown above the 2D spectra. There are clear
correlations between the Se atom and b protons on either side of the selenium bridge, confirming its position. (b) Ensemble of 10 NMR-derived solution
structures for 14 (green), the inactive SeLan 16 (orange) and synthetic OT (blue). The flexible C-terminus is shown in red. (c) Overlay of the OT ring
(residues 1–6) of 14 (green) and the crystal structure of ‘free’ (pink, PDB ID 1XY2) and bound OT (yellow, PDB ID 1NPO). (d) Overlay of the ring
(residues 1–6) of active 14 (green), inactive 16 (orange) and bound OT (yellow) showing the difference in the position of the Se bridge.
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Discussion
In this study, we introduced a methodology for macrocyclization
of peptides using non-reducible SeCtt crosslinkers that
synthetically overpowers the limited Ctt cyclization strategy.
The new procedure utilizes reductant DTT to release the highly
reactive selenolate from the diselenide peptide precursor, allowing
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Figure 6 | OT receptor expression and function in colonic nociceptors during CVH. (a) Colonic DRG neurons from healthy mice lack OT receptor (OTR)
expression (below the level of qRT–PCR detection), whereas expression of OT receptors is highly upregulated in colonic DRG neurons from CVH mice.
(b) Gel electrophoresis confirming the lack of detectable OT receptor in healthy colonic DRG neurons, but expression in colonic DRG neurons from
CVH mice. (c–e) In vitro luminal application of native OT (c), SeCtt 12 (d) and SeCtt 14 (e) had no effect at any dose on colonic nociceptor
mechanosensitivity in healthy mice (P40.05). (f) In CVH mice, native OT inhibits nociceptor mechanosensitivity (*Po0.05, n¼ 7). (g,h) In CVH mice,
SeCtt 12 (g) and SeCtt 14 (h) caused a dose-dependent inhibition of colonic nociceptors, fully reversing the mechanical hypersensitivity of CVH mice
(**Po0.01, ***Po0.001, one-way analysis of variance, Bonferroni post hoc test). (i) Native OT caused significantly greater nociceptor inhibition in
CVH mice compared with healthy mice relative to baseline responses (**Po0.01). (j) SeCtt 12 caused significantly greater nociceptor inhibition in
CVH mice relative to healthy mice at all doses tested (**Po0.01, ***Po0.001). (k) SeCtt 14 caused significantly greater nociceptor inhibition in CVH
mice relative to healthy mice at 10 nM (*Po0.05, 100 nM (***Po0.001) and 1,000nM (***Po0.001). All data are Mean±SEM.
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efficient selenoether crosslinking to take place under mild
conditions. The linear peptide precursor can be prepared using
either Boc or Fmoc-SPPS with the halogenated moiety incorpo-
rated by a chlorination step or coupling of a halogenated building
block. Selenide closure is chemoselective and can be applied to
unprotected peptides in aqueous media at RT without a catalyst.
This approach is particularly promising for the development of
disulphide-containing peptide-drug candidates, with the surro-
gate SeCtt linkage showing substantial higher stability without
disturbing the biological active structure of the OT peptide32.
The structure of ‘free’ OT was determined for the first time by
taking advantage of the unprecedented sensitivity of modern
NMR spectrometers. Compared with previous studies of OT
performed at 600MHz using a conventional probe, we achieved a
fourfold improvement in signal-to-noise by using a cryoprobe-
equipped 900-MHz spectrometer (in addition to linear improve-
ments in sensitivity at higher yields). In addition to being able to
extract an unprecedented number of dipolar couplings, significant
advances in predicting backbone dihedral angles of peptides and
proteins based on backbone chemical shifts (15N/13C/1H) allowed
us to extract critical backbone f and c angle restraints41. The
new NMR data revealed that native OT and bioactive SeCtt 12
have similar well-defined structures in aqueous solution; the
backbone of the OT rings (residues 1–6) are very similar, whereas
the predicted dynamic region overlays poorly (red in Fig. 5).
Surprisingly, the NMR structures overlay poorly with the crystal
structure of the free form of dOT (PDB ID 1XY2) but are in good
agreement with the crystal structure of OT bound to its carrier
neurophysin. The heterogeneity found in the ‘free’ crystal form
has been argued to be due to the inherent conformational
flexibility of OT34. Furthermore, the large difference between the
two crystal forms (0.9 Å) led to the suggestion that OT must
undergo a conformational change upon binding its receptor35.
However, the r.m.s.d. (root mean squared deviation) between the
‘free’ OT crystal structure and the NMR structure is B1.0 Å,
whereas the r.m.s.d. between the NMR structure of the active
forms of OT and the complex structure is only 0.3–0.5 Å. This
difference is apparent when the backbones of the active OT rings
are overlaid: the NMR and neurophysin-bound OT structures
overlay well, while the free crystal form is more compressed,
perhaps due to crystal packing forces (Fig. 5c). Thus, the new
NMR data are not consistent with OT undergoing a major
conformational change upon binding to neurophysin. Rather, the
backbone conformation of OT in aqueous solution appears to be
pre-optimized for receptor-binding. However, there are
significant differences between the side-chain orientations in the
neurophysin-bound OT structure and the NMR structure
(0.8–1.1 Å), consistent with these flexible solvent-exposed side
chains adopting a thermodynamically more favourable orien-
tation upon binding. The inactive SeLan 16 OT analogue, which
has a slightly shorter selenoether bridge in comparison to SeCtt
12, has a similar overall fold to the other active OT rings, but with
small perturbations in the positions of residues 1 and 2. The
spatial displacement of the Y2-Cb atom in SeLan 16 in
comparison with the Cb of bound OT (1NPO) is B2Å, while
in SeCtt 14 the corresponding displacement is only 0.1 Å. Since
the Y2 residue is critical for OT activity, these small structural
changes might explain the loss of agonist activity in SeLan 16.
It has generally been assumed that the reported analgesic
properties of OT in clinical studies of patients with abdominal
diseases9,10 are due to a central effect of OT. However, there is a
complete lack of evidence regarding the actual mechanism of
action. The work described here reveals a very different scenario,
whereby OT and OT analogues can act in the periphery on the
endings of nociceptive afferents innervating the colon. In healthy
mice, we were unable to detect expression of OT receptors in
colonic DRG neurons. However, we found that OT receptor
expression is massively upregulated in primary sensory DRG
neurons innervating the colon from mice with CVH. Consistent
with this high-level expression of OT receptors in CVH, in vitro
luminal administration of native OT and the stable SeCtt OT
analogues 12 and 14 were anti-nociceptive, as evidenced by their
ability to reduce colonic nociceptor mechanosensitivity in a
mouse model of chronic abdominal pain (Fig. 6g,h). This
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inhibitory effect was also blocked by the OT receptor antagonist
atosiban, which was also applied to the lumen of the colon. This is
an important finding as peripheral sensitization of nociceptors
has been shown to occur in IBS patients, which contributes to the
chronic nature of their symptoms54,55. This enhanced peripheral
signaling facilitates aberrant processing within the spinal cord59,
which influences the manifestation of pain referred to other
organs. Therefore, reducing peripheral signaling is an important
component of symptom treatment. Our results represent the first
definitive report of native OT, OT analogues and OT receptor
actions specifically on peripheral sensory afferent endings in the
colon. Critically, our in vitro data show that local luminal
absorption of native OT and OT analogues in gut tissue
significantly reduces colonic nociceptor function, without the
need for systemic effects, but only under conditions of chronic
abdominal pain. Correspondingly, we also show that intra-
colonic luminal application of OT analogues in vivo significantly
reduces signaling from colonic nociceptors into the spinal cord
but again only under conditions of chronic abdominal pain. We
found that mice intra-colonically administered with the OT
analogue SeCtt 14 have a reduced capacity to detect and signal
noxious CRD, as indicated by the reduction in activated DH
neurons within the thoracolumbar spinal cord. In particular,
fewer activated neurons were detected in the superficial lamina of
the DH, which is the major termination zone for nociceptive
afferents and consists of nociception-specific neurons responding
to noxious inputs from afferent fibres59. Importantly, the OT
analogue SeCtt 14 does not completely inhibit the capacity to
signal noxious CRD into the spinal cord in CVH mice; however,
it does reduce sensitivity to equivalent healthy levels. This is
important, given the physiological importance of these afferents
to detect and alert us to harmful events. Since we applied OT
analogues to the lumen of the colon over a relatively short
time period in both our in vitro and in vivo studies, their actions
are predominantly localized in a topical manner to the gut wall.
As such, we suggest that native OT and OT analogues act on
the peripheral endings of nociceptors innervating the wall of the
colon, thereby reducing the nociceptive signal at the first step
of the pain pathway. This is an important finding, as
targeting peptide therapeutics with poor oral bioavailability
to the gastrointestinal tract has been demonstrated to be an
effective approach for the clinical treatment of abdominal pain in
IBS patients47. Such approaches maximize the anti-nociceptive
effect of analgesic drugs to the site of action, the peripheral
endings of nociceptors in the colon wall, while reducing the
risk of systemic side effects. In this study, using the same
approach, we identified anti-nociceptive actions of native OT and
OT analogues that are of predictive clinical value for the
treatment of chronic abdominal pain. Our findings are
consistent with previous human studies where OT
administration had no effect on pain thresholds in healthy
subjects60 but reduced chronic abdominal pain and discomfort in
patients with IBS or chronic idiopathic constipation9,10.
Importantly, the current study provides a mechanistic basis for
these contrasting effects, whereby OT receptor expression and
function are significantly increased on colonic nociceptors during
states of chronic abdominal pain.
In conclusion, we improved OT stability by incorporating an
isosteric non-reducible selenoether bond and revealed an
unprecedented well-defined structure for free OT in solution
that might guide future development of mimetics. We demon-
strated that OT receptors are massively upregulated in mice with
CVH and that the selenoether OT analogues, which are more
resistant to redox degradation in the gut environment61,62 than
native OT, have analgesic activity in this model of chronic
abdominal pain.
Methods
Peptide synthesis. Detailed procedures for the solid-phase assembly, cleavage and
purification of the peptides are described in Supplementary Methods.
Synthesis of [UYIQN(cCl-hAla)PLG-CONH2]2 (5). The peptide sequence
Boc-Sec(MeBzl)-Tyr(OtBu)-Ile-Gln(Trt)-Asn(Trt)-Hse(OTBDMS)-Pro-Leu-Gly 2
was assembled on a Rink Amide-MBHA resin following the general Fmoc-SPPS
procedure (Supplementary Methods). Chlorination of the Hse residue was per-
formed as follow: PPh3 (10 equiv.) and Cl3CCN (10 equiv.) were dissolved in DCM
(1ml per 0.1 g resin) at 0 C. The cold solution was added to the resin and
chlorination was carried out overnight at RT. Finally, the peptide was cleaved off
the resin and purified using RP-HPLC or used directly for cyclization without
further purification. HR-MS calculated for [C88H136Cl2N24O24Se2þ 2H]2þ :
1072.4006; found 1072.3978.
Synthesis of CYIQN(cCl-hAla)PLG-CONH2 (6). The peptide sequence
Fmoc-Cys(Trt)-Tyr(BrZ)-Ile-Gln(Trt)-Asn(Trt)-Hse(OTBDMS)-Pro-Leu-Gly 3
was assembled on a Rink Amide-MBHA resin following the general Fmoc-SPPS
procedure (Supplementary Methods). After full assembly of the peptide, the Fmoc
group was removed by standard treatment with piperidine. Boc protection of the
free N-terminal amine was carried out by treatment of the resin with Boc2O
(10 equiv.) and N,N-Diisopropylethylamine (DIPEA) (10 equiv.) in N,N-Dime-
thylformamide (DMF) for 10min. The Boc group is preferred over the Fmoc group
for protecting the N-terminal amino group in order to avoid any future exposure of
the generated chloride moiety to base media. Chlorination was carried out by
treating the resin with PPh3 (10 equiv.) and Cl3CCN (10 equiv.) in DCM overnight
as described for compound 5. Finally, the peptide was cleaved from the resin and
purified using RP-HPLC. HR-MS calculated for [C44H69ClN12O12SþH]þ :
1025.4640; found 1025.4615.
Synthesis of (cBr-hAla)YIQNCPLG-CONH2 (7). The peptide sequence
Fmoc-Hse(OTBDMS)-Tyr(OtBu)-Ile-Gln(Trt)-Asn(Trt)-Cys(Trt)-Pro-Leu-Gly
was assembled on a Rink Amide-MBHA resin following the general Fmoc-SPPS
procedure (Supplementary Methods). After removal of the Fmoc group of Hse1 by
standard treatment with piperidine, Boc protection of the free N-terminal amine
was carried out by treatment of the resin with Boc2O (10 equiv.) and DIPEA
(10 equiv.) in DMF for 10min. Bromination of the Hse residue in 4 was performed
by treating the resin with PPh3Br2 (10 equiv.) in DCM (1ml per 0.1 g resin) at RT
overnight. Finally, the peptide was cleaved from the resin and purified using RP-
HPLC. HR-MS calculated for [C44H69BrN12O12SþH]þ : 1071.4115/1069.4135;
found 1071.4106/1069.4112.
Synthesis of [(cBr-hAla)YIQNUPLG-CONH2]2 (10). The peptide sequence
Tyr(BrZ)-Ile-Gln-Asn-Sec(MeBzl)-Pro-Leu-Gly was assembled on an MBHA resin
using Boc-SPPS (Supplementary Methods). Upon removal of the Boc group of
Tyr2, the resin was treated twice with 5% DIPEA in DMF for 2min then washed
with DMF. Fmoc-g-bromo-homoalanine 921 was coupled by combining the amino
acid (5 equiv.) with HOAt (5 equiv.) and DIC (5 equiv.) in DMF:DCM (1:1). The
resulting solution was added immediately to resin and the reaction mixture was
shaken slowly for 2 h. The solvent was drained and the coupling procedure was
repeated. After washing the resin with DMF, the N-terminal Fmoc group was
removed by treatment with 20% piperidine in DMF for 1min (2 ). TFA cleavage
of resin afforded crude peptide that was purified using RP-HPLC. HR-MS calcu-
lated for [C88H136Br2N24O24Se2þ 2H]2þ : 1116.3501/1117.3481; found 1116.3483/
1117.3455.
Synthesis of [(hU)YIQN(bCl-Ala)PLG-CONH2]2 (11). The peptide sequence
Boc-SeHcy(MeBzl)-Tyr(BrZ)-Ile-Gln-Asn-[bCl-Ala]-Pro-Leu-Gly was assembled
on an MBHA resin using Boc-SPPS (Supplementary Methods). The b-chloro-
alanine residue at position 6 was coupled in the following way: after removal of the
Boc group in Pro3, the resin was treated twice with 5% DIPEA in DMF for 2min
and then washed with DMF. Boc-b-chloro-alanine (5 equiv.) was preactivated for
2min with HOAt (5 equiv.) and DIC (5 equiv.) in DMF:DCM (1:1) and then
coupled to the resin for 1 h. Upon complete assembly of the nonapeptide, HF
cleavage of the resin afforded the crude peptide, which was either purified using
RP-HPLC or used directly for cyclization without further purification. HR-MS
calculated for [C88H136Cl2N24O24Se2þ 2H]2þ : 1072.4006; found 1072.3985.
Cyclization of the peptides under various pH conditions. Linear peptides (5, 6,
7, 10 or 11) were dissolved in 0.1% TFA solution to a concentration of 1mgml 1.
The peptide solutions were then diluted 10-fold in a buffer solution containing
DTT (40 equiv. for selenoether cyclization; 20 equiv. for thioether cyclization). The
buffer solutions used were as follows: 0.1M sodium phosphate buffer pH 3.0, 4.1,
5.5, 7.0, 8.3 or 9.8 or aqueous Na2CO3 (5mgml 1, pH 11.2). Cyclizations were
carried out at RT and monitored using RP-HPLC. Areas of peaks in analytical
HPLC chromatograms were measured and used to quantify the ratio of starting
material, cyclized product and side products and to determine the percentage
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conversion of linear precursors into cyclic products. Supplementary Figure 1 shows
the reaction time for the seleno-peptides at different pH. It was important to check
the level of DTT consumption throughout the cyclization step. Extra DTT (40
equiv.) was occasionally added to the reaction whenever total conversion of this
reagent to its oxidized form was detected using RP-HPLC. The presence of DTT
during thioether cyclization was not essential for reactions taking less than 6 h to
complete; however, it was beneficial for those with longer reaction times.
Synthesis of selenoether OT SeCtt (12). Crude peptide 11 (20mg,
0.00934mmol) was dissolved in 0.1M sodium phosphate buffer pH 8.3 (200ml)
containing DTT (170mg). Cyclization was allowed to take place over 3 days at RT,
with occasional addition of DTT (170mg) after the 1-day reaction. The solution
was then diluted twofold with water and the final cyclized peptide was purified
using RP-HPLC, affording 5.2mg of SeCtt 12 in 27% overall yield (from first
amino acid loading on resin). HR-MS calculated for [C44H68N12O12SeþH]þ :
1037.4318; found 1037.4295.
Synthesis of selenoether OT SeCtt (14). Crude peptide 5 (6.0mg, 0.0028mmol)
was dissolved in 0.1 M sodium phosphate buffer pH 5.5 (40ml) containing DTT
(50mg, 0.336mmol). Cyclization was allowed to take place over 24 h at RT. The
solution was then diluted twofold with water and the final cyclized peptide was
purified using RP-HPLC, affording 2.45mg of SeCtt 14 in 42% overall yield (from
first amino acid loading on resin). HR-MS calculated for [C44H68N12O12SeþH]þ :
1037.4318; found 1037.4302.
Synthesis of thioether OT Ctt (13). Crude peptide 7 (7.8mg, 0.0073mmol) was
dissolved in 0.1M sodium phosphate buffer pH 9.8 (50ml). Cyclization was
allowed to take place over 4 h at RT. The solution was then diluted twofold with
water and the final cyclized peptide 13 was purified using RP-HPLC, affording
1.0mg of 13 (overall yield: 14% from first amino acid loading on resin). HR-MS
calculated for [C44H68N12O12SþH]þ : 989.4873; found 989.4851.
Synthesis of thioether OT Ctt (15). Crude peptide 6 (4.1mg, 0.0040mmol) was
dissolved in a solution of Na2CO3 (5mgml 1, pH 11.2, 30ml). DTT (12mg,
0.078mmol) was added and cyclization was allowed to take place over 3 days at RT.
The solution was then diluted twofold with water and the final cyclized peptide was
purified using RP-HPLC, affording 0.77mg of 15 (overall yield: 19% from first
amino acid loading on resin). HR-MS calculated for [C44H68N12O12SþH]þ :
989.4873; found 989.4869.
Thermal stability assay. OT and SeCtt 12 and 14 were dissolved in 50mM
sodium phosphate buffer pH 7.0 to a concentration of 20 mM. An aliquot (750 ml)
of this solution was placed inside a glass vial, sealed and placed in an incubator at
55 C. Samples (75 ml) were taken at t¼ 0, 2, 9, 24, 48 and 72 h, quenched with 5%
TFA solution (20ml) and analysed using RP-HPLC. The area of the peak corre-
sponding to the starting peptide was measured and plotted as a percentage of the
area at t¼ 0 (Fig. 4a). The data were plotted as ln (% of remaining peptide) versus
time and the pseudo-first-order rate constant for degradation was used to calculate
the half-life of the peptides (OT: 52 h, SeCtt 12: 1,232 h, SeCtt 14: 272 h).
Stability in human plasma. Human plasma (Sigma) was centrifuged at
13,000 r.p.m. for 15min to separate lipids and then pre-warmed to 37 C for 15min
before use. A 50 ml aliquot of peptide solution (B500 mM in water) was mixed with
300ml plasma and incubated at 37 C. Samples (50 ml) were taken at t¼ 0, 1, 2, 4, 8
and 24 h, quenched with 100 ml of 2% TFA/50% acetonitrile in water, cooled at 4 C
for 30min and then centrifuged at 13,000 r.p.m. for 5min. The supernatant was
analysed via LC-MS using a Thermo Hypersil GOLD C18 2.1 100mm column
running at 0.3mlmin 1 with a gradient of 5–50% B over 30min. Eluting peptides
were detected using an API 150 mass spectrometer in positive ion mode within the
mass range 400–1,800Da. The area of the peak corresponding to the starting
peptide was measured and plotted as a percentage of the area at t¼ 0 (Fig. 4b). The
data were plotted as ln (% of remaining peptide) versus time, and the pseudo-first-
order rate constant for degradation was used to calculate the half-life of the
peptides (OT: 16 h, SeCtt 12: 60 h, SeCtt 14: 50 h).
Functional activity of the OT analogues. Intracellular Ca2þ mobilization in
response to OT and its SeCtt and Ctt analogues was assessed in SH-SY5Y human
neuroblastoma cells endogenously expressing OT receptors as previously descri-
bed63. SH-SY5Y cells were routinely cultured in RPMI media supplemented with
15% fetal bovine serum and plated at a density of 50,000 cells per well on black-
walled 384-well imaging plates 48 h prior to the assay. After removal of culture
media, SH-SY5Y cells were loaded with Calcium 4 No-Wash dye (Molecular
Devices, Sunnyvale, CA, USA) diluted in physiological salt solution (composition:
NaCl 140mM, glucose 11.5mM, KCl 5.9mM, MgCl2 1.4mM, NaH2PO4 1.2mM,
NaHCO3 5mM, CaCl2 1.8mM, HEPES 10mM) for 30min at 37 C. Ca2þ
mobilization in response to the addition of OT and its selenocysteine analogues
was measured using a FLIPRTETRA plate reader (Molecular Devices; excitation/
emission: 470–495 nm/515–575 nm) for 300 s. Raw fluorescence values after
addition of compounds were converted to DF/F values and the maximum increase
in fluorescence after addition of compound plotted as a function of concentration
using GraphPad Prism (version 5.03, San Diego, CA, USA). To establish
concentration-response curves, a 4-parameter Hill equation with variable Hill
coefficient was fitted to the data.
NMR spectroscopy. 1D 1H NMR spectra and 2D 1H–1H total correlation
spectroscopy (mixing time¼ 80ms), 2D 1H–1H NOESY (mixing time¼ 350ms)
and 1H–13C HSQC NMR spectra were recorded using samples dissolved in 95%
H2O/5% D2O on a Bruker AVANCE spectrometer equipped with a cryogenically
cooled probe, operating at 298 K and a 1H frequency of 900MHz. All 77Se
experiments were performed at a 1H frequency of 500MHz on a Bruker AVANCE
system equipped with a broadband probe. The chemical shifts of 77Se sites were
measured using 1H-77Se HMQC spectra; the optimal value of 1J(77Se-1H) was
determined to be 25Hz. These 2D experiments required, on average, 10 h of data
acquistion time. Chemical shifts were referenced to Sec, as previously described39.
All nonlabile 1H as well as aliphatic 13C and 77Se chemical shifts were assigned
(Supplementary Table 2).
Structure determination. NOESY spectra were assigned and structures were
calculated automatically using the torsion angle dynamics program CYANA v3.0
(ref. 40). 1H–1H distance restraints from NOESY data were supplemented with f
and c dihedral-angle restraints derived from 1H, 13C and 15N chemical shift data
(where available) using the program TALOSþ 41. Three new templates were added
to the CYANA default library in addition to a previously derived template for
oxidized SEC39. The new templates were as follows: (1) a C-terminal amidation
template; (2) a template based on selenomethionine where the S-C bond was
substituted with Se-C bond properties and the Se atom was deprotonated (SME);
(3) a template was generated based on the cysteine template where the S atom was
removed (NSC). Thus, the OT analogues were created by fusing the NSC residue
with either SEC or SME using distance restraints.
Colonic studies. For detailed descriptions of the methodology used, see the
Supplementary Methods section. Experiments involving animals were approved by
the Animal Ethics Committees of the Institute of Veterinary and Medical Science/
SA Pathology and The University of Adelaide.
CVH model. Intra-colonic TNBS (130 ml ml 1 in 30% ethanol, 0.1ml bolus) was
administered as described previously46,47,59. TNBS-treated mice were allowed to
recover for 28 days, at which stage inflammation had resolved and chronic colonic
afferent mechanical hypersensitivity was evident. These mice are termed CVH
mice. For more information, see the Supplementary Methods.
In vitro colonic primary afferent recording preparation. In vitro single-unit
extracellular recordings of action potential discharge were made from splanchnic
colonic afferents. These recordings were made from C57BL/6 healthy or CVH mice
using standard protocols43–47,56. Baseline mechanosensitivity was determined in
response to application of a 2-g von Frey hair (vfh) probe to the afferent receptive
field for 3 s. This process was repeated three to four times, separated each time by
10 s. Mechanosensitivity was then re-tested after the application of native OT (1,
10, 100 or 1,000 nM) or the OT analogues SeCtt 12 (1, 10, 100 or 1,000 nM) or
SeCtt 14 (1, 10, 100 or 1,000 nM), respectively. In all cases, peptides were applied to
the mucosal surface of the colon for a period of 5min at each concentration via a
small metal ring placed over the receptive field of interest. In some experiments, the
OT receptor antagonist atosiban (10 mM) was pre-incubated on the colonic lumen
for 10min before the addition of a combination of atosiban (10 mM) and SeCtt 14
(100 nM). Data are presented as spikes per s and are expressed as mean±s.e.m.
n indicates the number of individual afferents.
Retrograde labelling to identify colonic neurons in DRG. Healthy and CVH
mice of 16 weeks of age were anaesthetised with halothane and following midline
laparotomy, three injections (10 ml total, 26 s gauge Hamilton syringe) of the
fluorescent retrograde neuronal tracer cholera toxin subunit B conjugated to
AlexaFluor-555 (CTB AF-555; Invitrogen, Carlsbad, CA, USA; 0.5% in 0.1M
phosphate buffer saline (PBS), pH 7.4) were made sub-serosally within the wall of
the descending colon B2 cm from the anus44,45,59. The viscera were carefully
rinsed with sterile saline after each injection to ensure that dye was not
incorporated into structures other than the colon wall, and the overlying muscle
and skin were then sutured closed. Following surgery, but prior to regaining
consciousness, mice were given an analgesic (5mg kg 1 butorphanol
subcutaneously; Intervet, Australia) and an antibacterial (10mg kg 1
oxytetracycline; Pfizer, Groton, CT).
Dissociated DRG cell culture, laser capture microdissection. Mice were killed
by CO2 inhalation and DRGs from T10–L1 were surgically removed 4 days after
injections of fluorescent dye into the colon (CTB-AF-555). DRGs were digested
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with 4mgml 1 collagenase II (GIBCO, Invitrogen) and 4mgml 1 dispase
(GIBCO) for 30min at 37 C, followed by 4mgml 1 collagenase II for 10min at
37 C44,45. Neurons were mechanically dissociated into a single-cell suspension via
trituration through fire-polished Pasteur pipettes. Neurons were re-suspended in
Hanks’ buffered salt solution (GIBCO) and spot-plated on 50-mm Zeiss duplex
dishes (Carl Zeiss, Oberkochen, Germany) and then maintained at 37 C in 5%
CO2 for 2 h, allowing optimal cell adhesion44,45. Retrogradely labelled neurons
were isolated using a PALM Microlaser Technologies microdissection system
(Carl Zeiss) and catapulted directly into a lysis/stabilization buffer-containing
carrier RNA (4 ng l 1) (Qiagen, Valencia, CA, USA). RNA was isolated from LCM
cells using an RNeasy Micro-Kit (Qiagen) following the manufacturer’s
instructions.
Quantitative RT–PCR. Quantitative reverse transcription–polymerase chain
reaction (qRT–PCR) was performed using a Chromo4 (MJ Research, Waltham,
MA) real-time instrument attached to a PTC-200 Peltier thermal cycler (MJ
Research) and Opticon Monitor software (MJ Research). Qiagen QuantiTect SYBR
Green RT-PCR 1-step kits were used according to the manufacturer’s specifications
with the primers listed in the Supplementary Methods.
Colorectal distention and pERK immunohistochemistry. Mice received an
enema of either saline or SeCtt 14 (1,000 nM). Ten minutes later, under anaes-
thesia, a 4 cm CRD balloon catheter was inserted transanally into healthy or CVH
mice. After regaining consciousness, CRD was performed (80mmHg for 10 s, then
deflated for 5 s and repeated five times). Following killing via anaesthetic overdose,
mice underwent fixation by transcardial perfusion, and the thoracolumbar
(T10–L1) spinal cord was removed and cryoprotected. Frozen sections were cut
and incubated with monoclonal rabbit anti-pERK with AlexaFluorR488 used for
visualization.
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